Equity Overview
Price & Market Data
Price: $0.40
Daily Change: -$0.183 / 45.85%
Daily Range: $0.40 - $0.40
Market Cap: $20,734,382
Daily Volume: 10,000
Performance Metrics
1 Week: -31.41%
1 Month: -31.41%
3 Months: -31.41%
6 Months: -31.41%
1 Year: -15.15%
YTD: %
Details
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada.